1. The Benefits of Dual Inhibition of 5α Reductase
Bob Djavan, Vincenzo Mirone 
European Urology Supplements 
Volume 5, Issue 20, Pages (December 2006)
DOI: /j.eursup
Copyright © 2006 European Association of Urology Terms and Conditions

2. Fig. 1
Serum dihydrotestosterone (DHT) suppression in patients with benign prostatic hyperplasia (BPH) receiving dutasteride 0.5mg or finasteride 5mg [12].
European Urology Supplements 2006 5, DOI: ( /j.eursup )
Copyright © 2006 European Association of Urology Terms and Conditions

3. Fig. 2
Comparison of results from the 4-yr Proscar Long-Term Efficacy and Safety Study (PLESS) finasteride with the 2-yr pivotal dutasteride studies in men with benign prostatic hyperplasia (BPH). The vertical line in the PLESS data graphs represents the 2-yr time point for comparison purposes. (A) Symptoms (American Urological Association Symptom Index [AUA-SI]); (B) total prostate volume (TPV); (C) surgery; and (D) acute urinary retention (AUR) [14–16]. Reproduced with permission from Roehrborn et al. [15] and from McConnell et al. [16]. Copyright 1998 Massachusetts Medical Society.
European Urology Supplements 2006 5, DOI: ( /j.eursup )
Copyright © 2006 European Association of Urology Terms and Conditions

4. Fig. 3
The most frequent drug-related adverse events in a controlled comparator study in benign prostatic hyperplasia of dutasteride and finasteride [17].
European Urology Supplements 2006 5, DOI: ( /j.eursup )
Copyright © 2006 European Association of Urology Terms and Conditions